EA201591904A1 - НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK - Google Patents
НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERKInfo
- Publication number
- EA201591904A1 EA201591904A1 EA201591904A EA201591904A EA201591904A1 EA 201591904 A1 EA201591904 A1 EA 201591904A1 EA 201591904 A EA201591904 A EA 201591904A EA 201591904 A EA201591904 A EA 201591904A EA 201591904 A1 EA201591904 A1 EA 201591904A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dihydro
- hinazolinamina
- indol
- pyridin
- pirrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к производным N-(2,3-дигидро-1H-пирроло[2,3-b]пиридин-5-ил)-4-хиназолинамина и N-(2,3-дигидро-1H-индол-5-ил)-4-хиназолинамина формулы (I)где R, R, R, R, R, Rи А имеют значение, определенное в формуле изобретения. Соединения по настоящему изобретению применяются в качестве ингибиторов PERK. Настоящее изобретение также относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения в качестве активного ингредиента, а также применению указанных соединений в качестве лекарственного средства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13162362 | 2013-04-04 | ||
PCT/EP2014/056430 WO2014161808A1 (en) | 2013-04-04 | 2014-03-31 | Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591904A1 true EA201591904A1 (ru) | 2016-02-29 |
EA027811B1 EA027811B1 (ru) | 2017-09-29 |
Family
ID=48040101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591904A EA027811B1 (ru) | 2013-04-04 | 2014-03-31 | ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK |
Country Status (14)
Country | Link |
---|---|
US (1) | US9688662B2 (ru) |
EP (1) | EP2989091B1 (ru) |
JP (1) | JP6268276B2 (ru) |
KR (1) | KR102274755B1 (ru) |
CN (1) | CN105102450B (ru) |
AU (1) | AU2014247215B2 (ru) |
BR (1) | BR112015024971B1 (ru) |
CA (1) | CA2901267C (ru) |
EA (1) | EA027811B1 (ru) |
ES (1) | ES2638317T3 (ru) |
HK (1) | HK1215026A1 (ru) |
IL (1) | IL241808B (ru) |
MX (1) | MX367772B (ru) |
WO (1) | WO2014161808A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10968203B2 (en) | 2017-03-17 | 2021-04-06 | Genentech, Inc. | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530063B (zh) * | 2015-01-13 | 2017-01-18 | 北京赛特明强医药科技有限公司 | 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用 |
CA2989118A1 (en) * | 2015-05-08 | 2016-11-17 | Oklahoma Medical Research Foundation | Nitrofuran derivatives that induce apoptosis in breast cancer cells by activating protein expression |
US11026945B2 (en) | 2016-04-29 | 2021-06-08 | The Trustees Of The University Of Pennsylvania | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
PT3472165T (pt) | 2016-06-21 | 2023-12-12 | Nerviano Medical Sciences Srl | Derivados de n-(fenil substituído)-sulfonamida como inibidores da quinase |
CA3081548A1 (en) * | 2017-09-26 | 2019-04-04 | The Regents Of The University Of California | Compositions and methods for treating cancer |
US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
EP4051286A1 (en) | 2019-10-29 | 2022-09-07 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and compositions for treating uveal melanoma |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
WO2003051849A1 (fr) | 2001-12-19 | 2003-06-26 | Ube Industries, Ltd. | Procede de production de quinazoline-4-one et derive de celle-ci |
DE60328461D1 (de) | 2002-01-28 | 2009-09-03 | Ube Industries | Verfahren zur herstellung eines chinazolin-4-onderivats |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
GEP20084439B (en) | 2004-01-23 | 2008-07-25 | Amgen Inc | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof |
US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
CA2721944C (en) | 2008-04-24 | 2016-06-07 | F2G Ltd | Pyrrole antifungal agents |
UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
WO2011146748A1 (en) * | 2010-05-21 | 2011-11-24 | New York University | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase |
AU2011333472A1 (en) | 2010-11-26 | 2013-06-06 | Lupin Limited | Bicyclic GPR119 modulators |
-
2014
- 2014-03-31 US US14/782,091 patent/US9688662B2/en active Active
- 2014-03-31 BR BR112015024971-0A patent/BR112015024971B1/pt not_active IP Right Cessation
- 2014-03-31 EP EP14715255.7A patent/EP2989091B1/en active Active
- 2014-03-31 MX MX2015014025A patent/MX367772B/es active IP Right Grant
- 2014-03-31 EA EA201591904A patent/EA027811B1/ru not_active IP Right Cessation
- 2014-03-31 KR KR1020157027012A patent/KR102274755B1/ko active IP Right Grant
- 2014-03-31 ES ES14715255.7T patent/ES2638317T3/es active Active
- 2014-03-31 CA CA2901267A patent/CA2901267C/en active Active
- 2014-03-31 WO PCT/EP2014/056430 patent/WO2014161808A1/en active Application Filing
- 2014-03-31 JP JP2016505782A patent/JP6268276B2/ja not_active Expired - Fee Related
- 2014-03-31 CN CN201480019472.XA patent/CN105102450B/zh not_active Expired - Fee Related
- 2014-03-31 AU AU2014247215A patent/AU2014247215B2/en not_active Ceased
-
2015
- 2015-09-24 IL IL241808A patent/IL241808B/en active IP Right Grant
-
2016
- 2016-03-16 HK HK16103029.1A patent/HK1215026A1/zh not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10968203B2 (en) | 2017-03-17 | 2021-04-06 | Genentech, Inc. | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders |
Also Published As
Publication number | Publication date |
---|---|
KR20150138847A (ko) | 2015-12-10 |
JP6268276B2 (ja) | 2018-01-24 |
CA2901267C (en) | 2021-01-19 |
CA2901267A1 (en) | 2014-10-09 |
EA027811B1 (ru) | 2017-09-29 |
US20160039798A1 (en) | 2016-02-11 |
HK1215026A1 (zh) | 2016-08-12 |
AU2014247215A1 (en) | 2015-09-03 |
JP2016517845A (ja) | 2016-06-20 |
BR112015024971A2 (pt) | 2017-07-18 |
EP2989091A1 (en) | 2016-03-02 |
BR112015024971B1 (pt) | 2022-09-20 |
AU2014247215B2 (en) | 2018-05-10 |
US9688662B2 (en) | 2017-06-27 |
KR102274755B1 (ko) | 2021-07-08 |
CN105102450A (zh) | 2015-11-25 |
EP2989091B1 (en) | 2017-05-10 |
WO2014161808A1 (en) | 2014-10-09 |
MX367772B (es) | 2019-09-05 |
CN105102450B (zh) | 2018-03-09 |
MX2015014025A (es) | 2016-02-10 |
ES2638317T3 (es) | 2017-10-19 |
IL241808B (en) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK | |
EA201492112A1 (ru) | ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА | |
EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
EA201391239A1 (ru) | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
EA201490287A1 (ru) | Новые замещенные производные индола в качестве модуляторов гамма-секретазы | |
EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
EA201491671A1 (ru) | Гетероциклильные соединения | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201290655A1 (ru) | Новые производные замещенного бициклического триазола в качестве модуляторов гамма-секретазы | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
MD20150073A2 (ro) | Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK) | |
EA201600366A1 (ru) | Производные бензимидазол-пролина | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
MD20140072A2 (ru) | Новые пиррольные соединения, способ их получения и содержащие их фармацевтические композиции | |
EA201171066A1 (ru) | Новые замещенные производные бензоксазола, бензимидазола, оксазолопиридина и имидазопиридина в качестве модуляторов гамма-секретазы | |
EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
EA201591195A1 (ru) | Новые хинолоновые производные | |
EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
EA201691930A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |